Terapevt Arkh
-
Randomized Controlled Trial
[The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study].
The article presents the main results of a randomized, double-blind, parallel, placebo controlled trial of DAPA-CKD. ⋯ Thus, dapagliflozin demonstrated the ability, in comparison with placebo, to reduce the primary composite point and a number of secondary composite points in patients with both diabetic and non-diabetic CKD.
-
Randomized Controlled Trial
[Effect of vitamin D receptor activators on serum Klotho levels in 3b-4 stages chronic кidney disease patients: a prospective randomized study].
High risk of cardiovascular events is among leading problems in chronic kidney disease (CKD). Serum Klotho is supposed to be cardio- and nephroprotective; modification of its levels may be important in CKD. ⋯ Successful parathyroid hormone level control with vitamin D receptor activators was associated with higher serum Klotho, selective agents having shown greater effect. Long-term treatment with selective vitamin D receptor activators may contribute to cardiovascular calcification prevention by modifying Klotho levels.